公开(公告)号：US11957699B2

公开(公告)日：2024-04-16

申请号：US17264959

申请日：2019-07-30

申请人： INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

发明人： Wan Namkung ,  Sang Won Lee ,  Yo Han Seo ,  Chin Hee Mun

IPC分类号： A61K31/7048 ,  A61P1/18 ,  A61P13/12 ,  A61P17/04 ,  A61P27/02 ,  A61P29/00

CPC分类号： A61K31/7048 ,  A61P1/18 ,  A61P13/12 ,  A61P17/04 ,  A61P27/02 ,  A61P29/00

摘要： The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis.

公开(公告)号：US20240115532A1

公开(公告)日：2024-04-11

申请号：US18392229

申请日：2023-12-21

申请人： NANJING NUTRABUILDING BIO-TECH CO., LTD.

发明人： Ronghua YI ,  Kylin LIAO

IPC分类号： A61K31/198 ,  A23L33/175 ,  A61P27/02

CPC分类号： A61K31/198 ,  A23L33/175 ,  A61P27/02

摘要： The present invention provides methods and compositions for alleviating and preventing age-associated visual degeneration in a mammal, comprising administrating to the mammal in need thereof an effective amount of L-Ergothioneine, an analog or derivative thereof, or a pharmaceutically acceptable salt, acid, ester, polymer, analog or derivative thereof, as an active ingredient. In particular, the administration of L-Ergothioneine is capable of controlling subretinal choroidal neovascularization (CNV) level in the mammal's retina; activating Nrf2-mediated antioxidant genes to scavenge chronic reactive oxygen species and decrease vascular endothelial growth factor (VEGF) level in the mammal's retinal pigment epithelium (RPE); activating Nrf2-mediated antioxidant genes by lowering the damage induced by oxidative stress (OS) in the mammal's RPE; and/or inhibiting oxidation-induced epithelial-to-mesenchymal transition (EMT) to prevent epithelial fibrosis in RPE in mammals' RPE.

公开(公告)号：US11944662B2

公开(公告)日：2024-04-02

申请号：US18448650

申请日：2023-08-11

申请人： Stealth BioTherapeutics Inc.

发明人： Liping Liu ,  Shibo Tang ,  Xiaoling Liang

IPC分类号： A61K38/06 ,  A61K38/07 ,  A61K45/06 ,  A61P27/02 ,  A61P27/12 ,  C07K5/09 ,  C07K5/107

CPC分类号： A61K38/06 ,  A61K38/07 ,  A61K45/06 ,  A61P27/02 ,  A61P27/12 ,  C07K5/0817 ,  C07K5/1016

摘要： The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.

公开(公告)号：US11938223B2

公开(公告)日：2024-03-26

申请号：US17859820

申请日：2022-07-07

申请人： Incept, LLC

发明人： Peter Jarrett ,  Michael J. McGrath ,  Timothy S. Jarrett ,  Rami El-Hayek ,  Andrew C. Vanslette ,  Courtney A Rosales ,  Charles D. Blizzard ,  Amarpreet S. Sawhney

IPC分类号： A61K47/10 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4439 ,  A61P27/02

CPC分类号： A61K9/2072 ,  A61K9/0051 ,  A61K9/2031 ,  A61K31/4439 ,  A61K47/10

摘要： Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

公开(公告)号：US20240093188A1

公开(公告)日：2024-03-21

申请号：US17927427

申请日：2020-08-13

申请人： OliX Pharmaceuticals, Inc.

发明人： Sun Woo HONG ,  June Hyun PARK

IPC分类号： C12N15/113 ,  A61P27/02

CPC分类号： C12N15/113 ,  A61P27/02 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3515

摘要： The present disclosure relates to an RNAi-inducing nucleic acid molecule and use thereof. An aspect of the disclosure relates to an RNAi-inducing nucleic acid molecule for inhibiting expression of myeloid differentiation primary response gene 88 (MyD88). Another aspect of the present disclosure relates to a pharmaceutical composition for treating or preventing age-related macular degeneration, compri the RNAi-inducing nucleic acid molecule.

公开(公告)号：US20240091377A1

公开(公告)日：2024-03-21

申请号：US18517529

申请日：2023-11-22

申请人： Oculis Operations Sarl

发明人： Thorsteinn Loftsson ,  Zoltan Fulop

IPC分类号： A61K47/69 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/50 ,  A61K9/51 ,  A61K31/4184 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/34 ,  A61K47/38 ,  A61P27/02

CPC分类号： A61K47/6951 ,  A61K9/0048 ,  A61K9/08 ,  A61K9/10 ,  A61K9/146 ,  A61K9/50 ,  A61K9/51 ,  A61K31/4184 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/186 ,  A61K47/34 ,  A61K47/38 ,  A61P27/02 ,  A61K47/40

摘要： The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

公开(公告)号：US11931327B2

公开(公告)日：2024-03-19

申请号：US16628232

申请日：2018-07-03

申请人： Daiichi Sankyo Company, Limited

发明人： Naoki Tsuji ,  Masumi Ueno

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K31/192 ,  A61K31/24 ,  A61K31/415 ,  A61K31/4436 ,  A61K49/00 ,  A61P27/02 ,  C12N5/079 ,  G01N33/50

CPC分类号： A61K31/196 ,  A01K67/0275 ,  A61K9/0048 ,  A61K31/192 ,  A61K31/24 ,  A61K31/415 ,  A61K31/4436 ,  A61K49/0008 ,  A61P27/02 ,  C12N5/0621 ,  G01N33/5058 ,  A01K2217/05 ,  A01K2227/40 ,  A01K2267/0306

摘要： An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.

公开(公告)号：US20240082266A1

公开(公告)日：2024-03-14

申请号：US18509800

申请日：2023-11-15

申请人： Ocular Science, Inc.

发明人： Anthony SAMPIETRO ,  Damien GOLDBERG ,  Amy FROST ,  Brian HOLDORF

IPC分类号： A61K31/573 ,  A61K9/00 ,  A61K31/137 ,  A61K31/167 ,  A61K31/216 ,  A61K31/382 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5575 ,  A61P27/02

CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K31/137 ,  A61K31/167 ,  A61K31/216 ,  A61K31/382 ,  A61K31/407 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5575 ,  A61P27/02

摘要： Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

公开(公告)号：US20240082214A1

公开(公告)日：2024-03-14

申请号：US18348237

申请日：2023-07-06

申请人： Stewart Lebrun ,  Roxanne Chan ,  Sara Chavez

发明人： Stewart Lebrun ,  Roxanne Chan ,  Sara Chavez

IPC分类号： A61K31/375 ,  A61K47/02 ,  A61K47/36 ,  A61K47/42 ,  A61P27/02 ,  A61P39/06 ,  G01N33/50

CPC分类号： A61K31/375 ,  A61K47/02 ,  A61K47/36 ,  A61K47/42 ,  A61P27/02 ,  A61P39/06 ,  G01N33/502 ,  G01N33/5058 ,  G01N33/5088

摘要： The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (DoI) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

公开(公告)号：US11919913B2

公开(公告)日：2024-03-05

申请号：US17320158

申请日：2021-05-13

申请人： The Trustees of Columbia University in the City of New York

发明人： Konstantin Petrukhin ,  Christopher Cioffi ,  Graham Johnson ,  Nicoleta Dobri ,  Emily Freeman ,  Ping Chen ,  Michael Conlon ,  Lei Zhu

IPC分类号： C07D498/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61P27/02 ,  C07D401/06 ,  C07D405/14 ,  C07D409/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D495/04

CPC分类号： C07D498/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61P27/02 ,  C07D401/06 ,  C07D405/14 ,  C07D409/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D495/04

摘要： The present invention provides a compound having the structure:






wherein
R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl;
R4 is H, OH, or halogen;
B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole,

wherein the heterobicycle is other than chloro substituted indole; and
the pyrazole, when substituted, is substituted with other than trifluoromethyl,

or a pharmaceutically acceptable salt thereof.